{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:22:34Z","timestamp":1770391354010,"version":"3.49.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["METSY"],"award-info":[{"award-number":["METSY"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabinoid 1 receptor and glutamatergic dysfunction have both been implicated in the pathophysiology of schizophrenia. However, it remains unclear if cannabinoid 1 receptor alterations shown in drug-na\u00efve\/free patients with first episode psychosis may be linked to glutamatergic alterations in the illness. We aimed to investigate glutamate levels and cannabinoid 1 receptor levels in the same region in patients with first episode psychosis. Forty volunteers (20 healthy volunteers, 20 drug-na\u00efve\/free patients with first episode psychosis diagnosed with schizophrenia\/schizoaffective disorder) were included in the study. Glutamate levels were measured using proton magnetic resonance spectroscopy. CB1R availability was indexed using the distribution volume (V<jats:sub>T<\/jats:sub> (ml\/cm<jats:sup>3<\/jats:sup>)) of [<jats:sup>11<\/jats:sup>C]MePPEP using arterial blood sampling. There were no significant associations between ACC CB1R levels and ACC glutamate levels in controls (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.24, <jats:italic>p<\/jats:italic>\u2009=\u20090.32) or patients (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.10, <jats:italic>p<\/jats:italic>\u2009=\u20090.25). However, ACC glutamate levels were negatively associated with CB1R availability in the striatum (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.50, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and hippocampus (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2212\u00a00.50, <jats:italic>p<\/jats:italic>\u2009=\u20090.042) in controls, but these associations were not observed in patients (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Our findings extend our previous work in an overlapping sample to show, for the first time as far as we\u2019re aware, that cannabinoid 1 receptor alterations in the anterior cingulate cortex are shown in the absence of glutamatergic dysfunction in the same region, and indicate potential interactions between glutamatergic signalling in the anterior cingulate cortex and the endocannabinoid system in the striatum and hippocampus.<\/jats:p>","DOI":"10.1007\/s00406-020-01191-2","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T06:02:36Z","timestamp":1601272956000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-5226","authenticated-orcid":false,"given":"Faith","family":"Borgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Reis Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Lythgoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(98)07507-2","volume":"354","author":"TB Ust\u00fcn","year":"1999","unstructured":"Ust\u00fcn TB et al (1999) Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO\/NIH joint project CAR study group. Lancet (Lond Engl) 354:111\u2013115","journal-title":"Lancet (Lond Engl)"},{"key":"1191_CR2","first-page":"357","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY et al (2016) Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 12:357\u2013373","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1191_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-013-2994-z","volume":"227","author":"R Ayesa-Arriola","year":"2013","unstructured":"Ayesa-Arriola R et al (2013) Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology 227:615\u2013625","journal-title":"Psychopharmacology"},{"key":"1191_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY (1997) Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 14:1\u201320","journal-title":"Curr Med Res Opin"},{"key":"1191_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107704","author":"SJ Kaar","year":"2019","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD (2019) Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704","journal-title":"Neuropharmacology"},{"key":"1191_CR6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","volume":"51","author":"JI Friedman","year":"2002","unstructured":"Friedman JI et al (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349\u2013357","journal-title":"Biol Psychiatry"},{"key":"1191_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/jcp.0b013e318161318f","volume":"28","author":"JI Friedman","year":"2008","unstructured":"Friedman JI et al (2008) A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 28:59\u201363","journal-title":"J Clin Psychopharmacol"},{"key":"1191_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0619-6","author":"F Borgan","year":"2019","unstructured":"Borgan F et al (2019) The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-019-0619-6","journal-title":"Mol Psychiatry"},{"key":"1191_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD (2020) Schizophrenia: an Overview. JAMA Psychiatry 77:201\u2013210","journal-title":"JAMA Psychiatry"},{"key":"1191_CR10","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1007\/s00213-019-05283-3","volume":"236","author":"F Borgan","year":"2019","unstructured":"Borgan F et al (2019) The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology 236:3257\u20133270","journal-title":"Psychopharmacology"},{"key":"1191_CR11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29:97\u2013115","journal-title":"J Psychopharmacol"},{"key":"1191_CR12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","volume":"78","author":"DC Javitt","year":"2007","unstructured":"Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69\u2013108","journal-title":"Int Rev Neurobiol"},{"issue":"10","key":"1191_CR13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148(10):1301\u20138. https:\/\/doi.org\/10.1176\/ajp.148.10.1301","journal-title":"Am J Psychiatry."},{"key":"1191_CR14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","volume":"52","author":"JW Olney","year":"1995","unstructured":"Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998\u20131007","journal-title":"Arch Gen Psychiatry"},{"key":"1191_CR15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","volume":"33","author":"JW Olney","year":"1999","unstructured":"Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523\u2013533","journal-title":"J Psychiatr Res"},{"key":"1191_CR16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","volume":"17","author":"JM Stone","year":"2012","unstructured":"Stone JM et al (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry 17:664\u2013665","journal-title":"Mol Psychiatry"},{"key":"1191_CR17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881111405359","volume":"26","author":"MJ Taylor","year":"2012","unstructured":"Taylor MJ, Tiangga ER, Mhuircheartaigh RN, Cowen PJ (2012) Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol 26:733\u2013737","journal-title":"J Psychopharmacol"},{"key":"1191_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fpsyt.2018.00022","volume":"9","author":"KB Bojesen","year":"2018","unstructured":"Bojesen KB et al (2018) Glutamate levels and resting cerebral blood flow in anterior cingulate cortex are associated at rest and immediately following infusion of S-ketamine in healthy volunteers. Front psychiatry 9:22","journal-title":"Front psychiatry"},{"key":"1191_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopsych.2010.08.024","volume":"69","author":"JR Bustillo","year":"2011","unstructured":"Bustillo JR et al (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 tesla. Biol Psychiatry 69:19\u201327","journal-title":"Biol Psychiatry"},{"key":"1191_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0104-7","author":"J Kumar","year":"2018","unstructured":"Kumar J et al (2018) Glutathione and glutamate in schizophrenia: a 7T MRS study. Psychiatry Mol. https:\/\/doi.org\/10.1038\/s41380-018-0104-7","journal-title":"Psychiatry Mol"},{"key":"1191_CR21","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/appi.ajp.159.11.1944","volume":"159","author":"J Th\u00e9berge","year":"2002","unstructured":"Th\u00e9berge J et al (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944\u20131946","journal-title":"Am J Psychiatry"},{"key":"1191_CR22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/archpsyc.1997.01830220085012","volume":"54","author":"R Bartha","year":"1997","unstructured":"Bartha R et al (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54:959\u2013965","journal-title":"Arch Gen Psychiatry"},{"key":"1191_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0082-9","author":"A Egerton","year":"2018","unstructured":"Egerton A et al (2018) Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-018-0082-9","journal-title":"Mol Psychiatry"},{"key":"1191_CR24","first-page":"277","volume":"29","author":"T Chen","year":"2017","unstructured":"Chen T et al (2017) Abnormal concentration of GABA and glutamate in the prefrontal cortex in schizophrenia.-An in vivo 1H-MRS study. Shanghai Arch Psychiatry 29:277\u2013286","journal-title":"Shanghai Arch Psychiatry"},{"key":"1191_CR25","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1038\/s41598-019-45018-0","volume":"9","author":"FR Borgan","year":"2019","unstructured":"Borgan FR et al (2019) Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Sci Rep 9:8685","journal-title":"Sci Rep"},{"key":"1191_CR26","first-page":"1","volume":"2016","author":"J Wang","year":"2016","unstructured":"Wang J et al (2016) Reduced \u03b3 -aminobutyric acid and glutamate+glutamine levels in drug-na\u00efve patients with first-episode schizophrenia but not in those at ultrahigh risk. Neural Plast 2016:1\u20139","journal-title":"Neural Plast"},{"issue":"10","key":"1191_CR27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","volume":"5","author":"S Jauhar","year":"2018","unstructured":"Jauhar S, McCutcheon R, Borgan F, Veronese M, Nour M, Pepper F, Rogdaki M, Stone J, Egerton A, Turkheimer F, McGuire P, Howes O (2018) The relationship between cortical glutamate and striatal dopamine function in first episode psychosis: a multi-modal PET and MRS imaging study. Lancet Psychiatr 5(10):816\u2013823","journal-title":"Lancet Psychiatr"},{"key":"1191_CR28","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"L Herkenham","year":"1990","unstructured":"Herkenham L, Little J, Melvin, De Costa R (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci 87:1932\u20131936","journal-title":"Proc Natl Acad Sci"},{"key":"1191_CR29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/35069076","volume":"401","author":"RI Wilson","year":"2001","unstructured":"Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Marijuana affects brain function primarily by activating the G- protein-coupled cannabinoid receptor-1 (CB1). Lett to Nat 401:588\u2013592","journal-title":"Lett to Nat"},{"key":"1191_CR30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pnpbp.2014.01.019","volume":"52","author":"H Wang","year":"2014","unstructured":"Wang H, Lupica CR (2014) Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes. Prog Neuropsychopharmacol Biol Psychiatry 52:24\u201327","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1191_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: \u0394 9 -tetrahydrocannabinol, cannabidiol and \u0394 9 -tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215","journal-title":"Br J Pharmacol"},{"key":"1191_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(01)00372-5","volume":"31","author":"RI Wilson","year":"2001","unstructured":"Wilson RI, Kunos G, Nicoll RA (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31:453\u2013462","journal-title":"Neuron"},{"key":"1191_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00019.2008","volume":"89","author":"M Kano","year":"2009","unstructured":"Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309\u2013380","journal-title":"Physiol Rev"},{"key":"1191_CR34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00213-014-3841-6","volume":"232","author":"A Khani","year":"2015","unstructured":"Khani A et al (2015) Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making. Psychopharmacology 232:2097\u20132112","journal-title":"Psychopharmacology"},{"key":"1191_CR35","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/cercor\/bhx117","volume":"28","author":"B Guo","year":"2018","unstructured":"Guo B et al (2018) Chronic inflammatory pain impairs mglur5-mediated depolarization-induced suppression of excitation in the anterior cingulate cortex. Cereb Cortex 28:2118\u20132130","journal-title":"Cereb Cortex"},{"key":"1191_CR36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cercor\/11.8.728","volume":"11","author":"L Ferraro","year":"2001","unstructured":"Ferraro L et al (2001) The cannabinoid receptor agonist WIN 55,212\u20132 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 11:728\u2013733","journal-title":"Cereb Cortex"},{"key":"1191_CR37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1152\/jn.2001.85.1.468","volume":"85","author":"G Gerdeman","year":"2001","unstructured":"Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468\u2013471","journal-title":"J Neurophysiol"},{"key":"1191_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0374-8","author":"M Colizzi","year":"2019","unstructured":"Colizzi M et al (2019) Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-019-0374-8","journal-title":"Mol Psychiatry"},{"key":"1191_CR39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.neuron.2006.07.006","volume":"51","author":"K Monory","year":"2006","unstructured":"Monory K et al (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455\u2013466","journal-title":"Neuron"},{"issue":"5642","key":"1191_CR40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84\u20138","journal-title":"Science"},{"key":"1191_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1427","author":"F Borgan","year":"2019","unstructured":"Borgan F et al (2019) In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1427","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"1191_CR42","doi-asserted-by":"crossref","first-page":"e186893","DOI":"10.1001\/jamanetworkopen.2018.6893","volume":"2","author":"F Borgan","year":"2019","unstructured":"Borgan F, O\u2019Daly O, Huang K, Veronese M, Withers D, Batterham R, Howes O (2019) Neural responsivity to food cues in un-medicated first episode psychosis: an fMRI study. JAMA Netw Open 2(1):e186893","journal-title":"JAMA Netw Open"},{"key":"1191_CR43","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","volume":"79","author":"M Ranganathan","year":"2016","unstructured":"Ranganathan M et al (2016) Reduced brain cannabinoid receptor availability in schizophrenia. Biol Psychiatry 79:997\u20131005","journal-title":"Biol Psychiatry"},{"key":"1191_CR44","volume-title":"Wechsler adult intelligence scale","author":"D Wechsler","year":"1997","unstructured":"Wechsler D (1997) Wechsler adult intelligence scale, 3rd edn. The psychological corporation, San Antonio","edition":"3"},{"key":"1191_CR45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/arclin\/acq086","volume":"26","author":"C Gonzalez-Blanch","year":"2011","unstructured":"Gonzalez-Blanch C et al (2011) A digit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis. Arch Clin Neuropsychol 26:48\u201358","journal-title":"Arch Clin Neuropsychol"},{"key":"1191_CR46","unstructured":"First M, Spitzer R, Miriam G, Williams J (2007) Structured clinical interview of DSM-IV-TR AXIS I disoderss-patient edition (SCID-I\/P, 1\/2007 revision) (Biometrics research)"},{"key":"1191_CR47","volume-title":"Family interview for genetic studies (FIGS): a manual for FIGS: clinical neurogenetics branch","author":"E Maxwell","year":"1992","unstructured":"Maxwell E (1992) Family interview for genetic studies (FIGS): a manual for FIGS: clinical neurogenetics branch. Intramural research program, National institute of mental health"},{"key":"1191_CR48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276","journal-title":"Schizophr Bull"},{"issue":"1","key":"1191_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1744-859X-10-2","volume":"10","author":"IH Aas","year":"2011","unstructured":"Aas IH (2011) Guidelines for rating Global Assessment of Functioning (GAF). Ann Gen psychiatr 10(1):2. https:\/\/doi.org\/10.1186\/1744-859X-10-2","journal-title":"Ann Gen psychiatr"},{"key":"1191_CR50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.npp.1301402","volume":"33","author":"F Yasuno","year":"2008","unstructured":"Yasuno F et al (2008) The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology 33:259\u2013269","journal-title":"Neuropsychopharmacology"},{"key":"1191_CR51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuroimage.2014.04.020","volume":"97","author":"DA Ria\u00f1o Barros","year":"2014","unstructured":"Ria\u00f1o Barros DA et al (2014) Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. Neuroimage 97:151\u2013162","journal-title":"Neuroimage"},{"key":"1191_CR52","doi-asserted-by":"crossref","first-page":"e186893","DOI":"10.1001\/jamanetworkopen.2018.6893","volume":"2","author":"F Borgan","year":"2019","unstructured":"Borgan F et al (2019) Neural Responsivity to Food Cues in Patients With Unmedicated First-Episode Psychosis. JAMA Netw Open 2:e186893","journal-title":"JAMA Netw Open"},{"key":"1191_CR53","unstructured":"The Mathworks, I. MATLAB. (2010)"},{"key":"1191_CR54","first-page":"1936","volume":"47","author":"AJ Montgomery","year":"2006","unstructured":"Montgomery AJ et al (2006) Correction of head movement on PET studies: comparison of methods. J Nucl Med 47:1936\u20131944","journal-title":"J Nucl Med"},{"key":"1191_CR55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A et al (2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19:224\u2013247","journal-title":"Hum Brain Mapp"},{"key":"1191_CR56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0020-7101(93)90049-C","volume":"32","author":"D Feng","year":"1993","unstructured":"Feng D, Huang SC, Wang XM (1993) Models for computer-simulation studies of input functions for tracer kinetic modeling with positron emission tomography. Int J Biomed Comput 32:95\u2013110","journal-title":"Int J Biomed Comput"},{"key":"1191_CR57","first-page":"1","volume":"9294","author":"M Tonietto","year":"2018","unstructured":"Tonietto M et al (2018) A unified framework for plasma data modelling in dynamic positron emission tomography studies. IEEE Trans Biomed Eng 9294:1\u20131","journal-title":"IEEE Trans Biomed Eng"},{"key":"1191_CR58","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","volume":"37","author":"A Egerton","year":"2012","unstructured":"Egerton A et al (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37:2515\u20132521","journal-title":"Neuropsychopharmacology"},{"key":"1191_CR59","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","volume":"74","author":"SP Brugger","year":"2017","unstructured":"Brugger SP, Howes OD (2017) Heterogeneity and homogeneity of regional brain structure in schizophrenia. JAMA Psychiatry 74:1104","journal-title":"JAMA Psychiatry"},{"key":"1191_CR60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cercor\/bhj133","volume":"17","author":"DA Fortin","year":"2007","unstructured":"Fortin DA, Levine ES (2007) Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex 17:163\u2013174","journal-title":"Cereb Cortex"},{"key":"1191_CR61","doi-asserted-by":"crossref","first-page":"e3914","DOI":"10.1002\/nbm.3914","volume":"31","author":"C Gasparovic","year":"2018","unstructured":"Gasparovic C, Chen H, Mullins PG (2018) Errors in 1 H-MRS estimates of brain metabolite concentrations caused by failing to take into account tissue-specific signal relaxation. NMR Biomed 31:e3914","journal-title":"NMR Biomed"},{"key":"1191_CR62","unstructured":"IBM, C. Statistical parametric mapping software. IBM SPSS statistics for windows, version 22 (2013)"},{"key":"1191_CR63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3371\/CSRP.3.2.5","volume":"3","author":"C Lehoux","year":"2009","unstructured":"Lehoux C, Gobeil MH, Lef\u00e8bvre AA, Maziade M, Roy MA (2009) The five-factor structure of the PANSS: a critical review of its consistency across studies. Clin Schizophr Relat Psychoses 3:103\u2013110","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"1191_CR64","doi-asserted-by":"publisher","unstructured":"N\u00e9meth B, Ledent C, Freund TF, H\u00e1jos N. CB 1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212\u20132. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.07.003","DOI":"10.1016\/j.neuropharm.2007.07.003"},{"key":"1191_CR65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cercor\/bhj133","volume":"17","author":"DA Fortin","year":"2006","unstructured":"Fortin DA, Levine ES (2006) Differential Effects of Endocannabinoids on Glutamatergic and GABAergic Inputs to Layer 5 Pyramidal Neurons. Cereb Cortex 17:163\u2013174","journal-title":"Cereb Cortex"},{"key":"1191_CR66","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","volume":"76","author":"A Minichino","year":"2019","unstructured":"Minichino A et al (2019) Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis. JAMA Psychiatry 76:914\u2013923","journal-title":"JAMA Psychiatry"},{"key":"1191_CR67","unstructured":"Hampson AJ et al. Dual effects of anandamide on nmda receptor-mediated responses and neurotransmission. J. Neurochem. Lippincott\u2014Raven Publ"},{"key":"1191_CR68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuropharm.2013.11.018","volume":"79","author":"S Navakkode","year":"2014","unstructured":"Navakkode S, Korte M (2014) Pharmacological activation of CB1 receptor modulates long term potentiation by interfering with protein synthesis. Neuropharmacology 79:525\u2013533","journal-title":"Neuropharmacology"},{"key":"1191_CR69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.ftd.0000197091.07807.22","volume":"28","author":"F Musshoff","year":"2006","unstructured":"Musshoff F, Madea B (2006) Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 28:155\u2013163","journal-title":"Ther Drug Monit"},{"key":"1191_CR70","first-page":"60","volume":"1","author":"DC D\u2019Souza","year":"2016","unstructured":"D\u2019Souza DC et al (2016) Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimag 1:60\u201367","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimag"},{"key":"1191_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2018.10.013","author":"H Laurikainen","year":"2018","unstructured":"Laurikainen H et al (2018) Sex difference in brain CB1 receptor availability in man. Neuroimage. https:\/\/doi.org\/10.1016\/j.neuroimage.2018.10.013","journal-title":"Neuroimage"},{"key":"1191_CR72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EMP Poels","year":"2014","unstructured":"Poels EMP et al (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152:325\u201333212","journal-title":"Schizophr Res"},{"key":"1191_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5093048","volume":"2018","author":"MV Baez","year":"2018","unstructured":"Baez MV, Cercato MC, Jerusalinsky DA (2018) NMDA receptor subunits change after synaptic plasticity induction and learning and memory acquisition. Neural Plast 2018:1\u201311","journal-title":"Neural Plast"},{"key":"1191_CR74","first-page":"35","volume":"1","author":"RC Malenka","year":"1995","unstructured":"Malenka RC (1995) Review \u25a0 : LTP and LTD: dynamic and interactive processes of synaptic plasticity. Neurosci 1:35\u201342","journal-title":"Neurosci"},{"key":"1191_CR75","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/mrm.24922","volume":"72","author":"CT Rodgers","year":"2014","unstructured":"Rodgers CT et al (2014) Human cardiac 31 P magnetic resonance spectroscopy at 7 tesla. Magn Reson Med 72:304\u2013315","journal-title":"Magn Reson Med"},{"key":"1191_CR76","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mrm.21067","volume":"56","author":"R Otazo","year":"2006","unstructured":"Otazo R, Mueller B, Ugurbil K, Wald L, Posse S (2006) Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging. Magn Reson Med 56:1200\u20131210","journal-title":"Magn Reson Med"},{"key":"1191_CR77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2967\/jnumed.109.067074","volume":"51","author":"GE Terry","year":"2010","unstructured":"Terry GE et al (2010) Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med 51:112\u2013120","journal-title":"J Nucl Med"},{"key":"1191_CR78","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1523\/JNEUROSCI.0247-14.2014","volume":"34","author":"GG Szabo","year":"2014","unstructured":"Szabo GG et al (2014) Presynaptic calcium channel inhibition underlies CB1 cannabinoid receptor-mediated suppression of gaba release. J Neurosci 34:7958\u20137963","journal-title":"J Neurosci"},{"key":"1191_CR79","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK (2016) Nature of Glutamate Alterations in Schizophrenia. JAMA Psychiatry 73:665","journal-title":"JAMA Psychiatry"},{"key":"1191_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx180","author":"R McCutcheon","year":"2017","unstructured":"McCutcheon R, Beck K, Jauhar S, Howes OD (2017) Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. https:\/\/doi.org\/10.1093\/schbul\/sbx180","journal-title":"Schizophr Bull"},{"key":"1191_CR81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00702-007-0859-5","volume":"115","author":"L Watis","year":"2008","unstructured":"Watis L, Chen SH, Chua HC, Chong SA, Sim K (2008) Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. J Neural Transm 115:493\u2013511","journal-title":"J Neural Transm"},{"key":"1191_CR82","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2013.2437","volume":"70","author":"NV Kraguljac","year":"2013","unstructured":"Kraguljac NV, White DM, Reid MA, Lahti AC (2013) Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 70:1294","journal-title":"JAMA Psychiatry"},{"key":"1191_CR83","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4503-03.2004","author":"M Melis","year":"2004","unstructured":"Melis M et al (2004) Cellular\/molecular endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Nuerosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.4503-03.2004","journal-title":"J Nuerosci"},{"key":"1191_CR84","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/070674370104600610","volume":"46","author":"S Coodin","year":"2001","unstructured":"Coodin S (2001) Body mass index in persons with schizophrenia. Can J Psychiatry 46:549\u2013555","journal-title":"Can J Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-020-01191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-020-01191-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-020-01191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T01:30:18Z","timestamp":1632792618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-020-01191-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1007\/s00406-020-01191-2","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FB became an employee at COMPASS Pathways Plc after the completion of this work. This work is unrelated to COMPASS Pathways Plc., M.V., and T. M. reported no potential conflicts of interest. O.H. reported receiving investigator-initiated research funding from or participating in advisory or speaker meetings organized by AstraZeneca, Autifony, Bristol-Myers Squibb, Eli Lilly, Heptares, Janssen, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, RAND, and Roche. J.H. reported speaker fees in meetings organized by Orion Pharma, Lundbeck, and Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}